Press release
September 12, 2011
Therapy Cells Inc.
584 Main Street
Saint Helena, CA 94574
Patrick Casey BVSc, PhD, MRCVS
President and founding scientist
Leading Bio-Tech Firm Moves to US
Today leading New Zealand biotechnology company Therapy Cell Ltd announced it was moving
to the United States through its merger with Therapy Cells Inc (formerly DIII OTC Market).
This exciting Bio Tech/Med tech Company holds the exclusive technology that allows adult cells
from a specific tissue (e.g. Achilles tendon) to grow again from an individual to enact repair and
regeneration of that tissue.
Renowned scientist Dr Patrick (Paddy) Casey, who shares his time between the University of
Auckland and labs at UC Davis, has been appointed President and Chief Scientific Officer of
Therapy Cells Inc. Dr Casey said “To our knowledge we are the only company in the World that
has this proven technology, which is in a strong patent position and effectively by-passes the
need for Stem Cell Treatment. We are very excited about entering the US market and pursuing
FDA approval”.
An initial valuation of $30 million USD for this technology has been appraised currently. FDA
approval for clinical use of this technology in the Human will likely increase this factor by at
least 10 times.
The group headed by Dr Casey has very strong links to the San Francisco bay area. Therapy
Cells has collaborated with and has laboratories at University of California, Davis. “The natural
synergy and roll out is obvious” said President/CS Dr Paddy Casey.
Explaining that the safety and efficacy work of this transformational technology has been
completed in the FDA approved model species for athletic injury (the horse is the recognized
species for athletic injury in this case), Dr Casey explained that “We are anticipating FDA
approval of our process within 12 to 18 months maximum”
The company can be reached at info@therapycells.com, or www.therapycells.com or Facebook
page Therapy Cells.
These are exciting times indeed!
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.The words or phrases "would be," "would
allow," "intends to," "will likely result," "are expected to," "will continue," "anticipate," "expect," "estimate," "project," "indicate," "could," "potentially," "should," "believe,"
"considers," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in the forward-looking
statements as a result of a number of risks and uncertainties. These include the Company's historic lack of profitability, end user customer acceptance and actual demand,
which may differ significantly from expectations, the need for the Company to manage its growth, the need to raise funds for operations and other risks within the regulation of
the industry. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not
necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking
statements to reflect occurrences, developments, events or circumstances after the date of such statement.